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PMH4
A CoMPreHensive review of ePideMiology And eConoMiC studies for 
PAtients diAgnosed witH non-PsyCHotiC MAjor dePressive disorder
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To conduct a systematic review of literature in on epidemiology and 
economic studies for patients diagnosed with Non-Psychotic Major Depressive 
Disorder (MDD). MethOds: The initial search strategy was developed in the 
PubMed/Medline database, and was then translated for the Cochrane and Embase 
database searches. Search strings for epidemiology and economics studies for MDD 
were constructed using varied approaches that included the use of MeSH terms, 
as well as keywords that would afford the best retrieval. Search statements were 
then combined to produce a final search set. Additional parameters were placed on 
the final search strategy to limit the retrieval to articles written in English, involv-
ing human subjects and published between 2000 and 2010. Results: Our search 
revealed 289 articles for epidemiology and 200 articles for economic studies on 
MDD from PubMed/Medline/Embase/Cochrane databases. After removing dupli-
cates and non-relevant articles, 17 for epidemiology and 26 for economic studies 
were included in the final analysis. Fifteen studies on epidemiology were focused 
on MDD prevalence, one study was on cumulative incidence. Prevalence estimates 
were higher for lifetime than past year and ranged between 3.1% and 26.6% for life-
time prevalence and between 1.5% and 11.7% for past-year prevalence. Two studies 
examined burden of illness, one study budgetary impact of MDD, 14 studies exam-
ined cost effectiveness of MDD treatments, 3 studies examined cost utility analysis 
and 6 other studies examined retrospective claims analysis. cOnclusiOns: MDD 
prevalence was higher in the lifetime estimates, when compared to the estimates 
reflecting shorter time frames, although there appeared to be greater variability in 
the lifetime estimates. Overall, the cost of treating MDD varied with type of study, 
study time frame, study perspective, the year in which the costs were calculated, 
and the pharmacotherapy prescribed.
PMH5
evAluAtion of AssoCiAtions AMong BioMArkers, CorrelAtes And 
treAtMent effiCACy in CliniCAl studies in PAtients diAgnosed witH 
non-PsyCHotiC MAjor dePressive disorder: A literAture review
Greene N.1, Greene M.2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Georgia State 
University, Bethel, MA, USA
Objectives: To perform a systematic review of literature in peer-reviewed 
journals on clinical biomarkers, correlates and treatment efficacy in clinical 
studies on patients diagnosed with Non-Psychotic Major Depressive Disorder 
(MDD). MethOds: The initial search strategy was developed in the PubMed/Medline 
database and was then translated for the Cochrane and Embase database searches. 
Search strings for biomarkers, correlates and treatment efficacy in patients with 
MDD were constructed using varied approaches that included the use of MeSH 
terms, as well as keywords that would afford the best retrieval. Also included were 
search terms that used an asterisk as a wildcard applied to a word stem. Search 
statements were then combined to produce a final search set. Additional parameters 
were placed on the final search strategy to limit the retrieval to articles written in 
English, involving human subjects and published between 2000 and 2010. Results: 
The initial search revealed 871 articles from PubMed/Medline/Embase/Cochrane 
databases. After removing duplicates and non-relevant articles, the final articles 
that were included in the review were 131. Forty-eight studies examined biomarkers 
and primarily focused on the relationship between biomarkers and MDD treat-
ment response. Only 29 of the 48 studies found a significant association between a 
biomarker and treatment response. Twenty-nine studies examined MDD correlates 
such as comorbidity or demographic variables. A poorer response to treatment was 
found for those patients who experienced comorbid anxiety, irrespective of the 
type of treatment. Fifty-four studies focused on treatment efficacy and are divided 
into 3 groups: SSRIs only, SNRIs only, and a comparison across SSRIs, SNRIs, and 
bupropion. Overall, the SSRIs showed comparable efficacy when compared to each 
other or placebo. cOnclusiOns: Most of the biomarker studies examined associa-
tions between the serotonin transporter and response to various MDD treatments. 
The majority of efficacy studies found that the treatments that are within the class 
had comparable efficacy.
MentAl HeAltH – Cost studies
PMH6
tHe iMPACt of AntiPsyCHotiCs PolyPHArMACy on HeAltH CAre Costs 
of PeoPle witH MentAl disorders in são PAulo City, BrAzil
Razzouk D., Sousa A., Oliveira G.G., Cardoso A., Mari J.J.
Universidade Federal de Sao Paulo, SAO PAULO, Brazil
Objectives: Antipsychotics polypharmacy (AP) has been associated with more 
adverse drug effects, higher treatment costs, worse clinical outcomes and sudden 
death. Though, the frequency of such practice may reach 50 % in some clinical set-
tings. The aims of this study were to estimate AP costs and its influence on the direct 
costs of health care package in a sample of people with mental disorders in São Paulo 
city, Brazil. MethOds: We used a bottom-up approach for the estimation of direct 
costs according to public health service provider perspective. Direct costs included 
costs with accomodation (residential service), inpatient, outpatient and emergency 
services and treatment received in the previous month, in 147 subjects with mental 
disorders living in twenty residential services during the year 2011. We evaluated 
quality of life, social behavior problems, psychiatric diagnosis, severity of symptoms, 
sociodemographics characteristics and pattern of health service use. Results: AP 
was found in 38% of the sample and it was not related with gender, age, severity of 
psychiatric symptoms, quality of life and social behavior problems. Antipsychotics 
monotherapy costs were related with the type of antipsychotic: Atypical antipsychot-
vant articles, the final articles that were considered for review were 82 for treat-
ment response and 13 for risk factors. Fifty-one studies examined non-genetic 
factors, serotonin-related genetic factors and variety of genes and polymorphism 
biomarkers to determine their association with MDD treatment response. Thirty-
one studies focused on variables that were found to be associated with some 
aspect of MDD and their impact on treatment response and include: comor-
bidity (n= 12), demographic and socioeconomic (n= 6), and depression-related 
(n= 13) variables. Thirteen studies examined the risk factors for MDD. Of these, 2 
studies focused on the role of biomarkers in MDD risk. And, 11 studies focused 
on variables that were found to be associated with some aspect of MDD and 
their impact on MDD risk, and focused on comorbidity (n= 5), demographic and 
socioeconomic (n= 2), depression-related (n= 3), and environmental variables 
(n= 1). cOnclusiOns: The majority of the biomarker studies examined associa-
tions between the serotonin transporter, genes and polymorphisms in response 
to various MDD treatments. With respect to correlate studies, younger age of MDD 
onset, as well as family history of mood disorders, were both associated with a 
longer duration of MDD illness.
PMH2
lengtH of stAy And outCoMes for AdolesCents treAted for 
suBstAnCe use disorder: An AnAlysis of dose resPose using 
ProPensity sCores
Ciesla J.1, Mazurek K.2
1Northern Illinois University, DeKalb, IL, USA, 2University of Illinois, Champaign-Urbana, 
Champaign, IL, USA
Objectives: This research uses propensity score methods to identify the relation-
ship between amount of treatment and treatment outcome for adolescents with 
psychoactive substance use disorder (PSUD). The objective is to describe the dose 
response relationship in terms relevant in economic evaluation. Outcomes studies 
in this population show that longer treatment leads to more positive outcomes. 
The standard for residential programs is a minimum of 21 days of treatment and 
ideally up to 90 days. MethOds: The subjects are 377 adolescents who success-
fully completed primary treatment from 2004-2010. All were placed at ASAM level 
III.5 (Clinically-Managed, Medium/High Intensity Residential). The data are from 
treatment records and a 234-item questionnaire. The questionnaire responses were 
matched to variables in treatment records creating a rich source of pre-treatment 
characteristics. This research operationalizes dose with four one-month categories 
(1 dose= 1 month) to capture nonlinearities between service use and outcomes. The 
outcome is three-month post-treatment drug/alcohol abstinence. The categories 
were fairly even and captured 92% of variation in dose. The first stage of statistical 
analysis used multinomial logistic regression to predict dosage with pre-treatment 
variables while adjusting for characteristics influencing both dose and treatment 
outcome. Propensity scores were then created for each dosage category. The dose 
response relationship was assessed using a binomial logistic regression includ-
ing the four dose categories as dummy variables (lowest dose category as refer-
ence). Results: The overall relationship between dose and outcome was significant 
(p= 0.01) as were outcome improvements over the four doses. Improvements were 
significant (p≤ 0.01) decreasing as dose increased—Exp.(B) was1.204 (1.2 times 
more likely to abstain) for one month, 1.532 two months, 1.643 three months, and 
1.794 for four months (% correctly classified= 94.2; – 2LL= 44.712; Cox and Snell 
R2= 0.475.) cOnclusiOns: This research shows a significant dose response rela-
tionship between treatment length and treatment outcome with response dimin-
ishing on the margin.
PMH3
CliniCAl outCoMes of PAtients witH MAjor dePressive disorder 
treAted witH eitHer duloxetine or seleCtive serotonin reuPtAke 
inHiBitors in MexiCo
Hong J.1, Novick D.1, Montgomery W.2, Dueñas H.3, Peng X.4, Kadziola Z.5, Haro J.M.6
1Eli Lilly and Company, Windlesham, UK, 2Eli Lilly Australia Pty Ltd, West Ryde, Australia, 3Eli 
Lilly de Mexico, México D.F., Mexico, 4Eli Lilly and Company, Indianapolis, IN, USA, 5Eli Lilly 
GmbH, Vienna, Austria, 6Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, 
Barcelona, Spain
Objectives: To compare treatment outcomes in patients with major depressive dis-
order (MDD) treated with either duloxetine or a selective serotonin reuptake inhibi-
tor (SSRI) for up to 6 months in a naturalistic setting in Mexico. MethOds: Data in 
this post hoc analysis were taken from a 6-month prospective, non-interventional, 
observational study that included a total of 1,549 MDD patients without sexual 
dysfunction in twelve countries (N= 591 in Mexico). Depression severity was meas-
ured using the Clinical Global Impression (CGI) and the 16-item Quick Inventory of 
Depressive Symptomatology Self-Report (QIDS-SR16). Pain was measured using the 
pain related items of the Somatic Symptom Inventory (SSI), and quality of life (QoL) 
was measured using the EQ-5D instrument with the UK population tariff and the 
EQ-VAS. Probabilities of initiating duloxetine (vs. SSRIs), expressed as propensity 
scores, were first constructed using logistic regression. Mixed effects modelling 
with repeated measures (MMRM) analysis was then used to compare treatment 
effectiveness and QoL between the duloxetine (N= 168) and SSRI (N= 413) groups, 
controlling for the propensity scores and other patient characteristics. Results: 
The severity of depression was comparable between the two groups at baseline. 
Duloxetine-treated patients, however, had a higher level of pain severity and a 
lower level of QoL (EQ-5D) than SSRI-treated patients at baseline (p≤ 0.001). Both 
descriptive and MMRM regression analyses showed that patients treated with dulox-
etine had better outcomes during follow-up, compared with patients treated with 
SSRIs. At 6 months, duloxetine-treated patients had lower levels of CGI (2.25 vs. 
2.52, p= 0.005), QIDS-SR16 (3.95 vs. 5.35, p< 0.001), and SSI-pain related (8.52 vs. 9.64, 
p< 0.001), and higher levels of EQ-5D (0.92 vs. 0.87, p< 0.001) and EQ-VAS (64.62 vs. 
57.63, p= 0.006) (MMRM results). cOnclusiOns: Duloxetine-treated patients had 
better 6-months outcomes in terms of depression severity, pain and QoL, compared 
with SSRI-treated patients.
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ance with paliperidone palmitate that is related to less relapses, a better quality of 
life and reduced hospitalization costs.
MentAl HeAltH – Patient-reported outcomes & Patient Preference studies
PMH10
needs AssessMent of PAtients treAted in CoMMunity PsyCHosoCiAl 
Centers in são PAulo, BrAzil
Nascimento A.1, Velasco T.M.2, Oliveira M.S.C.1
1Faculdade de Ciências Medicas da Santa Casa de São Paulo, São Paulo, Brazil, 2Hospital Alemão 
Oswaldo Cruz, São Paulo, Brazil
Objectives: To describe the needs of patients treated at community psychosocial 
centers in Sao Paulo, Brazil. MethOds: Cross-sectional study with 373 patients who 
were attending psychosocial care activities at least three times per week in community 
psychosocial centers, during 2007-2008. Needs were assessed using the “Camberwell 
Assessment of Need” (CAN). Psychotic symptoms were assessed using the “Positive 
and Negative Symptom Schedule” (PANSS). Results: Mean age of patients was 40.0 
years (standard deviation, SD = 12.6 years); 57.6% were male, 57.9% had fundamental 
education, 40.5% have schizophrenia, 15.9% have worked during last 12 months and 
14.7% were living alone. Median time attending in community psychosocial centers 
was two years (range of 15 days to 30 years) and mean number of weekly therapeutic 
activities was 3.6 (SD = 2.3). The mean score for the total number of needs was 7.1 
(SD = 2.8), with a range of 0 to 15 (maximum = 22). Basic needs were reported by 38 
(10.2%) patients; at least one social need was reported by 90.9%. At least one function-
ing need was reported by 94.4% patients; 85.5% have at least one health need; 86.3% 
have at least one service need. Women showed higher number of needs than men (p 
= 0.02) and educational until fundamental level was also associated with more needs 
(p = 0.02). We did not observe associations between weekly activities, unemployment, 
age, diagnosis and number of needs. Patients with higher PANSS scores showed more 
needs (p < 0.001). cOnclusiOns: We observed higher number of needs than in stud-
ies conducted in Europe, in all conceptual domains assessed by CAN. Many patients 
showed needs related to health and services, despite the time that they were attending 
in community psychosocial centers. Patients’ needs should take in account in order 
to improve the quality of care offered in mental health services.
MentAl HeAltH – Health Care use & Policy studies
PMH11
CliniCAl PrACtiCe guideline MAjor dePressive disorder for generAl 
PrACtitioners
Kongsuk T.
Prasrimahabhodi Psychiatric Hospital, Ubon Ratchathani, Thailand
Objectives: To develop the clinical practice guideline major depressive disorder 
for general practitioners in primary and secondary health care setting included 
the diagnosis, differential diagnosis, severity classification and medical treat-
ments. MethOds: A list of 13 key elements of a CPG development process were 
developed that consisted of 1) setting the review teams; 2) determining the problems; 
3) determining health outcomes;4) evidence based literature review; 5) meeting to 
draft the CPG; 6) formulating draft of CPG; 7) apprising the content of CPG by experts; 
8) trail phase; 9) evaluating for trail phase; 10) developing the curricular for CPG train-
ing; 11) preparing for CPG training; 12) evaluating; and 13) improving the CPG related 
with evaluated results. Results: There were 3 main processes in clinical practice 
guideline major depressive disorder for general practitioners in primary and second-
ary health care setting (CPG-MDD-GP) which were 1) Assessment of major depres-
sive disorder (clinical assessment using 9Q screening tool and DSM-TR diagnostic 
criteria, differential diagnosis, diagnosis for major depressive disorder and coding 
of diagnosis); 2) Management of major depressive disorder; and 3) Management of 
hospitalized patients. General practitioners were satisfied with the CPG-MDD-GP in 
trial phase. A total of 416 general practitioners in all provinces were trained to use 
the CPG-MDD-GP then they would be followed and evaluated. Psychiatrists in psy-
chiatric hospitals/ institutes would be available for consultation from the general 
practitioners. cOnclusiOns: The CPG-MDD-GP should be distributed to all general 
practitioners in primary and secondary health care setting. Next step, it would be 
useful for developing the CPG for MDD in the tertiary health care setting.
PMH12
ContriBution of lAtin AMeriCA to MentAl HeAltH in PregnAnCy
Lorenzo L.S.1, Einarson A.2, Einarson T.R.3
1Psinapsys Psychiatric Private Center, La Plata, Argentina, 2The Hospital for Sick Children, 
University of Toronto, Toronto, Ontario, Canada, 3University of Toronto, Toronto, ON, Canada
Objectives: To identify and describe published articles dealing with issues of men-
tal health in pregnancy from Latin American counties MethOds: Medline, Embase 
and LILACS databases were searched for published studies originating from Latin 
America regarding mental health issues in pregnancy. Search terms included the 
names of all countries in the United States Census Bureau International Database + 
mental health + pregnancy. We included all research and review articles dealing with 
pregnancy and/or lactation, epidemiology of mental disorders, prevention or treat-
ment of mental disorders, outcomes assessment, and counseling/drug information 
dissemination. Excluded were papers dealing exlusively with postpartum depres-
sion, HIV transmission, induction of abortion, in vitro fertilization, contraception or 
the use of alcohol or drugs of abuse. Data were analyzed descriptively. Results: The 
search identified 701 studies; 110 (16%) met the criteria. The earliest was published 
in 1984 and the contribution has increased exponentially [Y= -1E-125*exp(0.1452X), 
where X is the year; R-squared= 0.97). The majority (n= 80; 73%) consisted of original 
research and the other 27% were reviews (23 overviews, 3 systematic reviews/meta-
analyses, 4 other). Most frequent topics were depression (37%) as well as mixed 
anxiety/depression (6%), mental health during pregnancy (32%;), psychotropic drug 
use in pregnancy (13%), suicidality (6%), and quality of life (1%). By country, 58 (53%) 
were produced by Brazil, followed by Mexico (n= 18, 17%), Chile (n= 10, 9%), Colombia 
ics costs were 167.4 times higher than typical antipsychotic costs. AP mean monthly 
costs per person varied with the type of association between antipsychotics: typical-
atypical associations costs were U$257.5± U$228.5, while mean costs between two 
typical antipsychotics were U$4.36 ± U$4.02. Polypharmacy added U$300.00 dolars per 
person per month to direct costs of health care (excluding accomodation). For each 
additional antipsychotic associated, it was observed an additional montlhy costs per 
person of U$87.5 in the total costs of health care package (health services, treatment 
and accomodation). cOnclusiOns: AP added substantial costs and risks to treat-
ment and to health care costs and quality. This should be taken in account in resource 
allocation in public policies, especially in low-resources settings.
PMH7
ModelizACión eConóMiCA del genotiPAdo del CitoCroMo P450 Con el 
test BrAinCHiP en el trAtAMiento de lA dePresión MAyor
Crespo C., Villacampa A., Brosa M.
Oblikue Consulting, Barcelona, Spain
ObjectivOs: BrainChip es un test genético que predice la respuesta al tratamiento 
farmacológico de la depresión mayor (DM) determinando los polimorfismos de las 
isoenzimas CYP450. El objetivo ha sido valorar la eficienciade la incorporación del 
test BrainChip previa a la prescripción farmacológica en DM tras fallo en primera 
línea. MetOdOlOgíAs: Se desarrolló un modelo de Markov de ciclos bimensuales para 
cada fármacode una cohorte hipotética depacientes adultos con DM tras fallo en prim-
era línea. La cohorte se adecuó a la distribución del mercado actual y a su modificación 
tras incorporar BrainChip. Los datos de eficacia (no respuesta, respuesta y remisión) 
provienen de revisiones de la literatura y el uso de recursos y costes fue adaptado para 
el análisis inicial a España. Se analizaron los resultados en un horizonte temporal de 1, 3, 
5, 7 y 10 años desde la perspectiva del sistema sanitario aplicando un descuento del 3% 
sobre los efectos y los costes (euros 2011). ResultAdOs: BrainChip mejora la remisión 
entre un 9,5%-11,7% y la respuesta entre 5,5%-10,2%, alcanzando a los 10 años una 
respuesta del 72%. Los pacientes con DM mejoran la calidad de vida con BrainChip entre 
0,04 y 0,25 años de vida ajustados por calidad. El coste de Brainchip se compensa a los 
2 años resultando siempre coste-efectivo a corto plazo y dominante a partir del tercer 
año, mostrando ahorros de 1399€ /paciente tras 10 años. cOnclusiOnes: BrainChip 
en DM es dominante, permite prescribir los tratamientos con menos riesgos y costes y 
más eficacia. El modelo desarrollado permitiría la adaptación del análisis a cualquier 
país de Latinoamérica utilizando datos de costos locales.
PMH8
Cost effeCtiveness of PAliPeridone PAlMitAte versus risPeridone 
long-ACting injeCtABle, QuetiAPine And olAnzAPine for tHe 
treAtMent of PAtients witH sCHizoPHreniA in ColoMBiA
Casallas C.1, Ariza J.G.2
1Universidad de la Sabana, Bogotá, Colombia, 2Janssen Cilag, Bogotá, Colombia
Objectives: Schizophrenia is a chronic disorder that requires long-term treatment 
with antipsychotic medication to minimize relapse and provide clinical benefit to 
patients. For patients with schizophrenia, non-adherence to medication is a risk factor 
for relapse and re-hospitalization. Long-acting Injectable (LAI) formulations of atypical 
antipsychotics provide constant medication delivery and the potential for improved 
adherence. The objective of this study is to assess the cost-effectiveness of paliperidone 
palmitate (PP) versus risperidone long acting injectable (RLAI), olanzapine (OP) and que-
tiapine (QP). MethOds: A Markov decision analytic model was developed to simulate 
multi-episode patients transitioning through different states on monthly basis over a 
5 year time horizon from the perspective of the Colombian Health System. Probability 
of relapse, level of adherence, side effects, utilities and treatment discontinuation were 
derived from scientific literature. Only direct costs were considered as medications, 
laboratory tests, relapses and adverse events by using national tariffs and prices from 
Ministry of Health medication database. Outcomes were measured as relapses rate and 
Quality Adjusted Life Years (QALY). Discount rate 3%, exchange rate (1 USD = 1,794 COP) 
and threshold considered 3xPIB per capita (USD 20,066 / QALY). Results: Total costs 
(USD): PP (13,338), RLAI (12,635), OP (11,481) and QP (13,247). Hospitalization relapses costs 
(USD): PP (3,276), RLAI (3,341), OP (4,881) and QP (6,840). QALY: PP (3.09), RLAI (3.00), OP 
(2.93) and QP (2.87). Relapses rate: PP (1.35), RLAI (1.38), OP (2.01) and QP (2.81). Incremental 
Cost Utility Ratios (ICUR: USD / QALY): PP vs. RLAI (4,517), PP vs. OP (6,713) and PP vs. QP 
(230). cOnclusiOns: Considering a willingness to pay of USD 20,066 per QALY, the 
incremental cost of PP versus other alternatives could be compensated by its incremen-
tal benefits in terms of relapses avoided and QALY gained. From Health Care Provider 
perspective, PP demonstrates savings in terms of less hospital setting relapsing costs.
PMH9
tHe Cost-effeCtiveness And Cost-utility of PAliPeridone PAlMitAte 
in tHe treAtMent of sCHizoPHreniA in guAteMAlA
Obando C.A.1, Gonzalez L.2, Muschett D.1
1Janssen, Panama City, Panama, 2Janssen, Raritan, NJ, USA
Objectives: To compare from the Guatemaltecan third payer perspective the cost-
effectiveness of paliperidone palmitate with oral quetiapine. MethOds: A Markov 
model was developed to assess the cost-effectiveness and the cost-utility of treat-
ments available for schizophrenia in Guatemala. The model was adjusted to reflect 
the compliance of the patient and the real world effectiveness of both treatments. A 
10 year time horizon was used. All direct medical costs relevant for the third payer 
were included. Four types of side effects were considered in the model: extrapy-
ramidal symptoms, weight gain, diabetes and tardive dyskinesia. Deterministic and 
probabilistic sensitivity analyses were performed. Results: Effectiveness outcomes 
were reported both in QALYs and relapses avoided. The costs were reported in the 
local currency Quetzales and all cost and outcomes were discounted at 5% per year. 
Paliperidone palmitate dominated oral quetiapine by being less expensive (14% less) 
and more effective (44% less relapses and 20% more QALYs). The sensitive analyses 
confirmed the robustness of the results. cOnclusiOns: Paliperidone palmitate 
appeared to be a cost-saving treatment option in comparison with oral quetiapine 
for patients with schizophrenia in Guatemala. The model reflected a better compli-
